AstraZeneca U.S. regulator approval for breast-cancer drug Etcamah
U.S. regulators approved AstraZeneca’s breast-cancer drug Etcamah for use in combination with therapies including Pfizer’s Ibrance and Eli Lilly’s Verzenio, in a development analysts at J.P. Morgan called a minor positive.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.